Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

ABSTRACT: ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

PROVIDER: PRJNA627124 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11579390.fastq.gz	Fastqsanger.gz
	SRR11579391.fastq.gz	Fastqsanger.gz
	SRR11579392.fastq.gz	Fastqsanger.gz
	SRR11579393.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

Project description:ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

| PRJNA627126 | ENA

ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control

Project description:ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control

| PRJNA627125 | ENA

ChIP-Seq for HOXB13 in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148928 | GEO

ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control

Project description:ChIP-Seq for FOXA2 in PC3 cell line with GSK treatment and VEH control

| PRJNA627123 | ENA

HOXB13 WT and G84E mass spectrometry

Project description:To identify potential cofactors of HOXB13 in suppressing lipogenic programs in prostate cancer cells, we performed tandem affinity purification followed by mass spectrometry analysis of WT and G84E HOXB13 expressed in LNCaP cells. Out of the HOXB13-enriched proteins are previously reported interactors such as AR and its cofactors FOXA1, GATA2, and NKX3. However, these interactions were not disrupted by G84E as compared to WT HOXB13. Interestingly, we found strong interactions of HOXB13 with HDAC1/3 and their corepressors NCoR1/2 and TBL1X. Notably, these interactions were drastically reduced by G84E mutation.

2023-03-11 | PXD030810 | Pride

ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148925 | GEO

ChIP-Seq for FOXA1 in LNCaP cell line with GSK treatment and VEH control

Project description:We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

2020-07-14 | GSE148926 | GEO

HOXB13 interactome in prostate cancer PC3 cell line

Project description:Transcription factors are one of the major groups of proteins whose suppression leads to tumor growth arrest. Different types of cancer express a specific set of transcription factors that establish and maintain specific gene expression patterns. In prostate cancer cells, one of the key transcriptional regulators is the HOXB13 protein, but its function has not been well characterized. In the present study, we searched for protein partners of HOXB13 by co-immunoprecipitation followed by high-throughput mass spectrometric analysis (IP/LC-MS) using the PC3 cell line as a source. This analysis revealed that the major partners of HOXB13 were transcription factors with different types of DNA-binding domains.

2025-11-06 | PXD059115 | Pride

GSK-inhibitor treatment in IMR32 neuroblastoma cell line

Project description:GSK-inhibitor treatment in IMR32 neuroblastoma cell line

| PRJEB4227 | ENA

GSK-3 inhibitor treatment effect on MLL leukemia cell

Project description:Human leukemia cell line RS4.11 was treated with GSK-3 inhibitor SB216763 for 20 hours. Gene expression profiling was performed to analyze genes affected by GSK-3 inhibition. Human leukemia cell line RS4.11 was grown in vitro and treated with 10 uM GSK-3 inhibitor SB216763 or solvent DMSO for 20 hours. Total RNA was extracted and microarray analysis was performed. Two controls and three inhibitor treatment samples were analyzed.

2010-05-27 | E-GEOD-19736 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data